← Back to Search

CAR T-cell Therapy

NeoTCR-P1 adoptive cell therapy for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by PACT Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment using specially modified immune cells called NeoTCR-P1 T cells. These cells are designed to find and destroy cancer cells in patients with solid tumors. The study aims to see if this treatment is safe and effective. These modified T cells have shown promise in treating cancers with unique mutations.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of manufacturing NeoTCR-P1
Incidence of adverse events as defined as DLTs
Maximum Tolerated Dose (MTD) of NeoTCR-P1
+1 more
Secondary study objectives
Duration of Response mediated by neoTCR-P1 administered as a single agent or in combination with nivolumab to participants with solid tumors
Objective Response Rate (ORR) in participants with solid tumors following infusion of NeoTCR-P1 as a single agent or in combination with nivolumab
Overall survival (OS) in participants with solid tumors following infusion of NeoTCR-P1 as a single agent or in combination with nivolumab
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: NeoTCR-P1 plus nivolumabExperimental Treatment2 Interventions
Single dose of NeoTCR-P1 plus nivolumab 480mg IV every four weeks for up to 6 doses.
Group II: NeoTCR-P1 plus IL-2Experimental Treatment2 Interventions
Single dose of NeoTCR-P1 plus IL-2 500,000 IU/m2 SC twice daily (BID) for 7 days.
Group III: NeoTCR-P1Experimental Treatment1 Intervention
Single dose of NeoTCR-P1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
nivolumab
2016
Completed Phase 3
~4960
IL-2
2007
Completed Phase 4
~1100

Find a Location

Who is running the clinical trial?

PACT Pharma, Inc.Lead Sponsor
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top